CORRECTING and REPLACING Mountain Valley MD Announces Appointment of Advisors and Stock Option Grants

TORONTO–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. The updated release reads: MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS AND STOCK OPTION GRANTS Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) announces that it is issuing this amended and updated news release to correct … [Read more…]

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the closing of its previously announced private placement … [Read more…]

SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026

Ultrasensitive, structural variant-based ctDNA monitoring reliably tracks therapeutic response and predicts progression in metastatic breast cancer, and is a strong independent prognostic marker in advanced ovarian cancers MORRISVILLE, N.C.–(BUSINESS WIRE)–#AACR—SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, today announced that the company … [Read more…]

Groundbreaking Meeting of Minds at Northwell Health’s Quantum Biology Forum Unlocks New Understanding of Life’s Fundamental Principles

Gathering at United Therapeutics headquarters in Silver Spring, MD catalyzes interdisciplinary collaboration, highlighting quantum mechanics’ role in health and disease MANHASSET, N.Y.–(BUSINESS WIRE)–What if healing wasn’t just about chemistry, but about the very energy and light within our bodies? This groundbreaking question guided Northwell Health’s Quantum Biology Forum, a seminal first meeting of minds held … [Read more…]

Colgate-Palmolive Webcasts 2026 First Quarter Earnings Conference Call May 1, 2026 – 8:30 a.m. ET

NEW YORK–(BUSINESS WIRE)–Colgate-Palmolive Company (NYSE:CL) will provide a live webcast of its 2026 first quarter earnings conference call on Friday, May 1, 2026, at 8:30 a.m. ET. The call will be hosted by Chairman, President and CEO, Noel Wallace, Chief Financial Officer, Stan Sutula, Executive Vice President, Investor Relations, Claire Ross, and Executive Vice President, … [Read more…]

Pulse Biosciences to Host Analyst Event on April 25, 2026

Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on … [Read more…]

Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.–(BUSINESS WIRE)–#BKV–Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause … [Read more…]

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for … [Read more…]

Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease

52-week Phase 3 trial evaluating the efficacy and safety of sonlicromanol, a novel brain-penetrant redox-modulator with anti-ferroptotic and anti-inflammatory properties, in adult patients with the most common genetic defect causing primary mitochondrial disease, m.3243A>G Primary endpoints focus on most bothersome and frequently occurring effects of disease – chronic fatigue and muscle weakness – supported by … [Read more…]

Simplify Healthcare®, Sagility, and Convey Health Solutions Announce Strategic Alliance to Launch Sagility Synchrony

AURORA, Ill.–(BUSINESS WIRE)–Simplify Healthcare®, a Simplify Group™ company and a leading organization in the healthcare payer technology space, today announced a strategic alliance with Sagility and Convey Health Solutions (Convey) to launch Sagility Synchrony, a purpose-built, end-to-end Medicare Advantage lifecycle solution. Sagility Synchrony replaces fragmented point solutions with a Sagility-led, end-to-end managed services model powered … [Read more…]